209 related articles for article (PubMed ID: 30181243)
1. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
2. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.
Qian X; Esteban L; Vass WC; Upadhyaya C; Papageorge AG; Yienger K; Ward JM; Lowy DR; Santos E
EMBO J; 2000 Feb; 19(4):642-54. PubMed ID: 10675333
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.
Yang MH; Tran TH; Hunt B; Agnor R; Johnson CW; Shui B; Waybright TJ; Nowak JA; Stephen AG; Simanshu DK; Haigis KM
Cancer Res; 2023 Oct; 83(19):3176-3183. PubMed ID: 37556505
[TBL] [Abstract][Full Text] [Related]
5. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38641404
[TBL] [Abstract][Full Text] [Related]
6. Silencing KRAS Overexpression in Cadmium-Transformed Prostate Epithelial Cells Mitigates Malignant Phenotype.
Ngalame NN; Waalkes MP; Tokar EJ
Chem Res Toxicol; 2016 Sep; 29(9):1458-67. PubMed ID: 27510461
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
8. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
[TBL] [Abstract][Full Text] [Related]
9. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.
Puliga E; De Bellis C; Vietti Michelina S; Capeloa T; Migliore C; Orrù C; Baiocchi GL; De Manzoni G; Pietrantonio F; Reddavid R; Fumagalli Romario U; Ambrogio C; Corso S; Giordano S
Gastric Cancer; 2024 May; 27(3):473-483. PubMed ID: 38261067
[TBL] [Abstract][Full Text] [Related]
10. The renewed battle against RAS-mutant cancers.
Zhang F; Cheong JK
Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
[TBL] [Abstract][Full Text] [Related]
11. Membrane-Driven Dimerization of the Peripheral Membrane Protein KRAS: Implications for Downstream Signaling.
Lee KY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473778
[TBL] [Abstract][Full Text] [Related]
12. Biophysical Characterization of RAS-SOS Complexes by Native Mass Spectrometry.
Yun S; Scott E; Laganowsky A
Methods Mol Biol; 2024; 2797():177-193. PubMed ID: 38570460
[TBL] [Abstract][Full Text] [Related]
13. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis.
Zhang R; Peng X; Du JX; Boohaker R; Estevao IL; Grajeda BI; Cox MB; Almeida IC; Lu W
Cancer Res; 2023 Nov; 83(22):3739-3752. PubMed ID: 37695315
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach.
Min J; Vega PN; Engevik AC; Williams JA; Yang Q; Patterson LM; Simmons AJ; Bliton RJ; Betts JW; Lau KS; Magness ST; Goldenring JR; Choi E
Nat Commun; 2019 Dec; 10(1):5549. PubMed ID: 31804471
[TBL] [Abstract][Full Text] [Related]
16. RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
Castel P; Dharmaiah S; Sale MJ; Messing S; Rizzuto G; Cuevas-Navarro A; Cheng A; Trnka MJ; Urisman A; Esposito D; Simanshu DK; McCormick F
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34380736
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic Studies of KRAS in Complex with Small Molecules and RAS-Binding Proteins.
Chan AH; Simanshu DK
Methods Mol Biol; 2024; 2797():47-65. PubMed ID: 38570452
[TBL] [Abstract][Full Text] [Related]
18. PAQR10 and PAQR11 mediate Ras signaling in the Golgi apparatus.
Jin T; Ding Q; Huang H; Xu D; Jiang Y; Zhou B; Li Z; Jiang X; He J; Liu W; Zhang Y; Pan Y; Wang Z; Thomas WG; Chen Y
Cell Res; 2012 Apr; 22(4):661-76. PubMed ID: 21968647
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and Biochemical Characterization of Structurally Diverse Small Molecule Hits for KRAS Inhibition.
Pagba CV; Gupta AK; Dilsha K; Sadrpour P; Jakubec J; Prakash P; van der Hoeven D; Cho KJ; Gilbertson S; Gorfe AA
Chembiochem; 2024 Apr; 25(7):e202300827. PubMed ID: 38349283
[TBL] [Abstract][Full Text] [Related]
20. Mechanoactivation of NOX2-generated ROS elicits persistent TRPM8 Ca
Pratt SJP; Lee RM; Chang KT; Hernández-Ochoa EO; Annis DA; Ory EC; Thompson KN; Bailey PC; Mathias TJ; Ju JA; Vitolo MI; Schneider MF; Stains JP; Ward CW; Martin SS
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26008-26019. PubMed ID: 33020304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
